BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 12009868)

  • 1. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
    Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
    Cox JH; Ferrari MG; Earl P; Lane JR; Jagodzinski LL; Polonis VR; Kuta EG; Boyer JD; Ratto-Kim S; Eller LA; Pham DT; Hart L; Montefiori D; Ferrari G; Parrish S; Weiner DB; Moss B; Kim JH; Birx D; VanCott TC
    Vaccine; 2012 Feb; 30(10):1830-40. PubMed ID: 22234262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
    Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM
    J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
    Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
    McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
    J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques.
    Habel A; Chanel C; Le Grand R; Martinon F; Couillin L; Moog C; Doms R; Gauduin MC; Hurtrel B; Guillet JG; Aubertin AM; Girard M
    Dev Biol (Basel); 2000; 104():101-5. PubMed ID: 11713807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.
    Barouch DH; Santra S; Kuroda MJ; Schmitz JE; Plishka R; Buckler-White A; Gaitan AE; Zin R; Nam JH; Wyatt LS; Lifton MA; Nickerson CE; Moss B; Montefiori DC; Hirsch VM; Letvin NL
    J Virol; 2001 Jun; 75(11):5151-8. PubMed ID: 11333896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
    Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
    Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
    Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
    Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge.
    Bogers WM; Niphuis H; ten Haaft P; Laman JD; Koornstra W; Heeney JL
    AIDS; 1995 Dec; 9(12):F13-8. PubMed ID: 8605046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.
    Kim JJ; Yang JS; Nottingham LK; Lee DJ; Lee M; Manson KH; Wyand MS; Boyer JD; Ugen KE; Weiner DB
    Virology; 2001 Jul; 285(2):204-17. PubMed ID: 11437655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
    Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
    Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.